Redcare Pharmacy Shares Hit Lowest Valuation in Half a Decade

Redcare Pharmacy cuts margin targets, hitting a 5-year stock low. Despite strong Rx growth, competition from Rossmann and dm intensifies in the digital health market.

Shares of online pharmacy operator Redcare Pharmacy are facing intense pressure. A combination of heightened competitive threats and a significant reduction in profitability targets has severely impacted the company's market valuation. The management is being forced to make difficult concessions as traditional drugstore chains like Rossmann and dm expand into the digital health sector.

The immediate catalyst for the recent sell-off was the annual results presentation in early March. In a surprising move, the company slashed its medium-term target for its adjusted EBITDA margin from over 8% to just over 5%. This revision, coupled with a fourth-quarter margin of only 1.6% that fell well short of market expectations, prompted investors to withdraw capital. The consequence was stark: by Friday, the stock price had plunged to a new five-year low of €33.54, representing a loss of approximately 50% since the start of the year.

Operational Strengths and Political Tailwinds

Despite the challenging environment, Redcare's core prescription business shows robust growth. Last year, its revenue from prescription medications (Rx) in Germany nearly doubled to €503 million. Leadership anticipates this segment will generate over €670 million in the current year, fueled by the adoption of digital prescriptions (E-Rezept) and the Health ID.

Furthermore, potential regulatory changes could provide relief. Federal Health Minister Nina Warken has proposed increasing the flat fee per digital prescription to €9.50. For Redcare, such a policy shift would translate almost directly into improved operating profit.

On the operational front, the company is preparing for higher volume. A new logistics center in Plze?, Czech Republic, is set to boost annual shipping capacity for over-the-counter products by up to 15 million packages.

Mounting Competitive Pressures

The market landscape is becoming increasingly crowded. Following dm's plans, competitor Rossmann now aims to launch its own online pharmacy in 2026, operating from the Netherlands. Rossmann brings a formidable domestic reach to Redcare's home market, with approximately 11 million app users.

However, a key regulatory distinction currently protects Redcare's business model: Rossmann will not offer prescription-only medicines. This Rx segment is precisely where Redcare is experiencing its most significant growth, insulating it somewhat from this new competitive front.

Signs of Stabilization and Forthcoming Catalysts

Early indicators suggest some market sentiment may be stabilizing. Data from analytics firm Hazeltree reveals that institutional short-sellers have recently reduced their short positions by more than 10%.

Two key events in the coming weeks will be critical for the company's strategic direction. At the Annual General Meeting on April 15, 2026, shareholders will vote on a proposed overhaul of the Supervisory Board, where three long-standing members are slated to be replaced by new candidates. Then, on May 6, the focus will shift back to financial performance. The quarterly results will demonstrate whether the momentum in the crucial prescription business continues and if the company remains on track to meet its revised margin targets for the year.